ClinicalTrials.gg
RecruitingNCT07570862RECLAIM-LNUpdated Sep 14, 2026

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

A Phase 2 interventional study of FT819 in Lupus Nephritis, Systemic Lupus Erythematosus and SLE - Systemic Lupus Erythematosus, sponsored by Fate Therapeutics. Recruiting at 12 sites in United States. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Fate Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
47th of 100
53 · median 50
Started
2026
with 14 others
Phase 2
34 of 114
7 open now
Primary completion
2029-07
later than 34 of 49 live
Registered
109th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 47th largest by planned enrollment of the 100 interventional ones that give a count, is one of 15 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 34 of the 49 other live ones, and was the 109th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.

Read the detailed description

This is a multicenter, phase 2 single-arm trial designed to evaluate the efficacy and safety of FT819 in participants with moderate-to-severe systemic lupus erythematosus (SLE) with Class III/IV lupus nephritis (LN) (with or without concomitant Class V involvement) refractory to at least 2 immunosuppressive therapies prior to trial intervention.

Participants will undergo a screening period of up to 28 days. Following screening, trial intervention will consist of bendamustine administration followed by a single dose of FT819. Efficacy, safety, and exploratory assessments will be conducted at predefined timepoints through Month 24 of post-treatment follow-up (PTFU). Following completion of these scheduled assessments, participants will continue in long-term follow-up (LTFU) for up to 15 years after FT819 administration to monitor ongoing safety and survival.

Efficacy and disease activity will be assessed using standard LN measures, including complete renal response (CRR) and PRR (partial renal response), as well as clinician-reported outcomes, such as the SLEDAI-2K, BILAG, and PGA, performed at specified timepoints.

03

Conditions studied

  • Lupus Nephritis
  • Systemic Lupus Erythematosus
  • SLE - Systemic Lupus Erythematosus
  • Lupus Nephritis - WHO Class III
  • Lupus Nephritis - WHO Class IV

Keywords

  • FT819
  • Fate Therapeutics
  • Allogeneic CAR T
  • CD19 - targeted therapy
  • Lupus Nephritis
  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥12 to ≤70 years
  • Diagnosis of SLE per EULAR/ACR 2019 classification criteria
  • -proven proliferative Class III or IV LN, with or without concomitant Class V involvement, based on the 2003/2018 ISN/RPS classification
  • Positivity for at least one of the following autoantibodies at screening:

    1. Antinuclear antibody (ANA)
    2. Anti-double-stranded DNA (anti-dsDNA) or
    3. Anti-Smith antibody
  • Active disease, defined as:

    a. Evidence of SLE activity, defined as either: i. SLEDAI-2K ≥6 or ii. At least 1 BILAG A or 2 BILAG B scores for SLE-related organ involvement; and b. Evidence of renal involvement, defined as UPCr ≥1 g/g; and c. Moderate-to-severe renal disease with investigator's impression that improvement is possible

  • to ≥2 systemic therapies for the treatment of LN

Exclusion criteria

EXCLUSION CRITERIA:

  • Evidence of inadequate organ function during the screening period
  • Active central nervous system (CNS) symptoms attributable to disease within 12 months prior to trial intervention
  • History of or current renal diseases (other than LN) that, in the opinion of the investigator, could interfere with assessment of LN or confound evaluation of disease activity
  • Receipt of dialysis (hemodialysis or peritoneal dialysis) within 12 weeks of trial intervention
  • Irreversible organ damage related to underlying disease (e.g., ESRD) where, in the opinion of the investigator, CD19 CAR T-cell therapy would be unlikely to benefit the participant
  • History of in the prior 5 years
  • Known allergy to the following FT819 components: albumin (human) or DMSO
  • History of intolerance or to bendamustine
  • Body weight \<30 kg
  • Any medical condition, clinical laboratory abnormality, or nonmedical/social issue that, per investigator or medical monitor judgement, precludes safe participation in and completion of the trial or that could affect compliance with protocol conduct or interpretation of results
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    FT819

    FT819, allogeneic T cells derived from a clonal, TCR knockout iPSC line that express CD19-targeted CAR regulated by the TRAC locus, given as a single IV infusion

    Biological: FT819

Interventions

  • BiologicalFT819

    Single Intravenous (IV) infusion of FT819 administered on Day 1

06

What researchers measure

Primary outcomes

  1. Complete Renal Response (CRR) at Week 26

    Proportion of participants achieving CRR at Week 26, with CRR defined as the achievement of all of the following criteria: * UPCR \<0.5 g/g * Estimated glomerular filtration rate (eGFR) ≥85% of baseline or ≥60 mL/min/1.73 m2 * No use of rescue therapy

    Time frame: Week 26

Secondary outcomes

  1. CRR at Week 52

    Proportion of participants who achieve CRR at Week 52

    Time frame: Week 52

  2. CRR at Week 104

    Proportion of participants who achieve CRR at Week 104

    Time frame: Week 104

  3. Overall Renal Response

    Proportion of participants who achieve an overall renal response, defined as achievement of either CRR or partial renal response (PRR), evaluated at Week 26, Week 52, and Week 104

    Time frame: Up to approximately 2 years

  4. Proportion of participants who achieve PRR at Week 26, Week 52, and Week 104

    PRR is defined as achievement of all of the following: * ≥50% reduction in UPCr from baseline and to \<3 g/g if baseline UPCr ≥3 g/g * eGFR ≥80% of baseline or ≥60 mL/min/1.73 m2 * No use of rescue therapy

    Time frame: Up to approximately 2 years

  5. Lupus Low Disease Activity State (LLDAS)

    Proportion of participants who achieve lupus low disease activity state (LLDAS) at Week 26, Week 52, and Week 104

    Time frame: Up to approximately 2 years

  6. Definition of Remission in SLE (DORIS)

    Proportion of participants who achieve a definition of remission in SLE (DORIS) at Week 26, Week 52, and Week 104

    Time frame: Up to approximately 2 years

  7. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue (adults age ≥18 years) score at Week 26, Week 52, and Week 104

    Time frame: Up to approximately 2 years

  8. Proportion of participants who achieve SLE Responder Index-4 (SRI-4)

    Proportion of participants who achieve SLE Responder Index-4 (SRI-4) at Week 26, Week 52, and Week 104

    Time frame: Up to approximately 2 years

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 35 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartActual
Jul 27, 2026
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jan 31, 2030
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570862
Lead sponsor
Fate Therapeutics
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jul 27, 2026
Primary completion
Jul 1, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Sep 14, 2026

Study contacts

Fate Clinical Trials
Contact
clinicaltrials@fatetherapeutics.com
858-875-1800
Natalie Shiff, MD
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819

Start the discussion